Cardiff Oncology Details Strong Phase 2 Data for Onvansertib in mCRC, Outlines Registrational Path

summarizeSummary

Cardiff Oncology disclosed detailed positive Phase 2 clinical trial results for onvansertib in first-line RAS-mutant metastatic colorectal cancer, showing a 72% objective response rate and favorable progression-free survival trends, and outlined its strategy for a registrational Phase 3 trial.

check_boxKey Events

• Positive Phase 2 Data Detailed

  Detailed CRDF-004 trial results for onvansertib in first-line RAS-mutant mCRC showed a 72% confirmed objective response rate (ORR) in the 30 mg arm, a 30% improvement over standard of care (FOLFIRI SoC).

• Favorable Survival Trends Reported

  Median progression-free survival (PFS) has not yet been reached in the onvansertib + FOLFIRI/bev arms, with a compelling hazard ratio of 0.37 (p=0.048) versus standard of care.

• Registrational Trial Strategy Outlined

  The company plans an FDA meeting in H1 2026 to finalize the registrational program, with a Phase 3 trial (CRDF-005) expected to initiate in H2 2026, comparing onvansertib + FOLFIRI/bev to standard of care.

• No Significant Added Toxicity

  The CRDF-004 trial data indicated no significant added toxicity with onvansertib, supporting its safety profile for combination therapy.

auto_awesomeAnalysis

This 8-K provides critical details of the positive Phase 2 CRDF-004 trial for onvansertib, which were previously only broadly mentioned in the February 24, 2026 8-K. The reported 72% objective response rate and favorable progression-free survival trends in first-line RAS-mutant metastatic colorectal cancer (mCRC) are highly significant, especially for a company that recently disclosed a "going concern" warning in its 10-K filed on February 24, 2026. The clear outline of the registrational Phase 3 trial design and planned FDA meeting in the first half of 2026 provides a concrete path forward for the company's lead asset. This positive clinical development is crucial for addressing the company's financial viability and could significantly impact investor sentiment and future financing prospects.